Skip Ribbon Commands
Skip to main content

Karen Crasta

Karen Crasta-01 (Custom).jpg

Nanyang Associate Professor Karen Crasta
PhD
National Research Foundation Fellow
Principal Investigator, Genomic Instability and Cancer​ Laboratory​​
Email: kccrasta@ntu.edu.sg 

 

 

Team 
  • Rekha Jakhar, PhD, Research Fellow
  • Monique Luijten, PhD, Research Fellow
  • Jocelyn Teo, Research Assistant
  • Alex Wong Xing Fah, PhD Student
  • Qianqian He, PhD Student

 

Introduction

Associate Professor Karen Crasta is a Nanyang Associate Professor of Molecular and Cellular Biology at the Lee Kong Chian School of Medicine (LKCMedicine), Nanyang Technological University (NTU). She is also Joint Principal Investigator at NTU School of Biological Sciences and Agency for Science, Technology and Research (A*STAR), Institute of Molecular and Cell Biology (IMCB).

After obtaining her BSc (Honors in Microbiology) at the National University of Singapore (NUS), she went on to receive her PhD in Cell Cycle Regulation at the Institute of Molecular and Cell Biology, NUS where she studied the molecular circuits governing regulation of mitotic spindle assembly using budding yeast as a model system. She then undertook post-doctoral training at the Dana-Farber Cancer Institute (DFCI), Harvard Medical School in Boston, USA where she elucidated the mechanistic link between chromosome missegregation during mitosis and tumourigenesis in cancer cells. Upon her return to Singapore, she joined A*STAR, IMCB as a Senior Research Fellow to further her interests in examining genomic instability in human cancers.

A/Prof Crasta was awarded the A*STAR International Fellowship from Singapore during her stint at Harvard. She has also been awarded the prestigious National Research Foundation (NRF) Fellowship and the Elite Nanyang Assistant Professorship (NAP).

 
Research Focus
 
​​
How does chromosomal instability (aneuploidy, point mutations and structural changes such gene rearrangements or translocations) lead to tumour development and other age-associated diseases? Why is aging the biggest risk factor for cancer? How do stromal cells participate in cancer progression?  How do tumours acquire resistance to chemotherapy? What can we do to prevent the side-effects and toxicity of chemotherapy? 

A/Prof Crasta's lab seeks to answer these fascinating questions and more! They aim to integrate personalised medicine into clinical practice from a chromosomal instability perspective. In elucidating the role of abnormal mitosis in cancer, their work has led to insights into how antimitotic therapy-induced senescence can lead to immune evasion and chemoresistance. They seek to better understand the impact on age-related tumour microenvironment (TME) on tumour cell intrinsic mechanisms and vice versa, as well study the influence of external environmental/lifestyle influences (such as physical exercise, drug toxicity) on genome plasticity and immune function. The laboratory is situated at the Experimental Medicine Building in the beautiful NTU campus and is equipped with state-of-the-art facilities.  Cell  and molecular biology, biochemistry, high-resolution microscopy, high-content screening, chromosomal analyses, animal and patient-related approaches are used to tease apart and solve challenging questions. A/Prof Crasta’s research involves multi-disciplinary teams consisting of basic and translational scientists, clinicians, engineers and industry partners.
  
The lab's research aims to identify novel cellular targets that could be of relevance to the development of combination therapies to improve sensitization of tumour cells, as well as provide insights into chemoresistance, a major setback in oncology. The lab has recently identified a novel route to chemoresistance upon antimitotic chemotherapy (most-commonly used front-line therapy in a wide spectrum of cancers). Current studies are now focused on elucidating the influence on immune function (both innate and adaptive), understanding the impact of the tumour microenvironment in dictating cell death versus survival during chemotherapy, as well as profiling global genomic, transcriptomic, proteomic and lipidomic changes. Results obtained will aid illuminate the role of abnormal mitosis/aneuploidy and associated altered cell signaling, metabolic and immune changes in cancer progression and therapy.
 



 
Selected Publications​

Shyu PJ, Wong AXF, Crasta KC, et al. (2018). Dropping in on lipid droplets: insights into cellular stress and cancer progression. Bioscience Reports. (In press)

He Q, Au B, ..., & Crasta KC. (2018). Chromosomal instability-induced senescence potentiates cell non-autonomous tumourigenic effects. Oncogenesis. (In press)

Jakhar R, Luijten MNH, ..., & Crasta KC. (2018). Autophagy governs pro-tumourigenic effects of mitotic slippage-induced senescence. Molecular Cancer Research.

Luijten MNH, Lee JXT, & Crasta KC. (2018). Mutational game changer: Chromothripsis and its emerging relevance to cancer.​ Mutatation Research/Reviews in Mutation Research. 777:29-51. 

Luijten MNH, Lee JXT, ..., & Crasta KC. (2018). Generation of micronuclei and detection of chromosome pulverization. Methods in Molecular Biology. 1769:183-95.

Cheng B, & Crasta K. (2017). Consequences of mitotic slippage for anti-microtube therapy. Endocrine-Related Cancer. 24(9):T97-T106.

Crasta K, & Aneja R. (2017). 50 years on... the delivery of tubulin advances cancer treatment. Endocrine-Related Cancer. 24(9): E3-E5.

Cheng B, & Crasta K. (2017). Autophagy, senescence and cancer In E. Wong (Ed.), Autophagy and Signalling (71-96) in Autophagy and Signaling. Boca Raton, FL, CRC Press/Taylor & Francis.

Crasta K,Ganem NJ, Dagher R, et al. (2012). DNA breaks and chromosome pulverization from errors in mitosis. Nature. 482:53-58.






Not sure which programme to go for? Use our programme finder
Loading header/footer ...